226 related articles for article (PubMed ID: 26333382)
1. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
2. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
[TBL] [Abstract][Full Text] [Related]
3. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
[TBL] [Abstract][Full Text] [Related]
4. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK
Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256
[TBL] [Abstract][Full Text] [Related]
5. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Wilson EA; Sultana N; Shah KN; Elford HL; Faridi JS
Mol Cancer Ther; 2021 Apr; 20(4):655-664. PubMed ID: 33536192
[TBL] [Abstract][Full Text] [Related]
6. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
8. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
9. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A
Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
12. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
13. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.
Jin K; Kong X; Shah T; Penet MF; Wildes F; Sgroi DC; Ma XJ; Huang Y; Kallioniemi A; Landberg G; Bieche I; Wu X; Lobie PE; Davidson NE; Bhujwalla ZM; Zhu T; Sukumar S
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2736-41. PubMed ID: 21690342
[TBL] [Abstract][Full Text] [Related]
14. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
15. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
[TBL] [Abstract][Full Text] [Related]
19. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]